- Smith & Nephew said it had completed its acquisition of regenerative medicine products supplier Osiris for around $660m.

The medical technology group had offered $19.00 per Osiris share in cash.

Osiris delivered revenue of $142.8m for the year through December, up 21% on-year.

At 2:43pm: [LON:SN.] Smith Nephew PLC share price was -16.75p at 1472.25p

Story provided by